Published in Front Physiol on May 15, 2014
The physiology of vitamin D-far more than calcium and bone. Front Physiol (2014) 0.76
Measurement of circulating 25-hydroxyvitamin D: A historical review. Pract Lab Med (2015) 0.75
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A (2008) 11.71
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer (2007) 10.20
THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol (1927) 7.64
Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer (2007) 6.18
An E2F/miR-20a autoregulatory feedback loop. J Biol Chem (2006) 5.20
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal (2010) 4.15
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
Cellular fatty acid metabolism and cancer. Cell Metab (2013) 2.82
Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol (2005) 2.73
Vitamin D for cancer prevention: global perspective. Ann Epidemiol (2009) 2.61
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol (2011) 2.45
A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci U S A (1998) 2.34
hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol Cancer (2005) 2.21
Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med (2010) 1.98
Association of vitamin D status with serum androgen levels in men. Clin Endocrinol (Oxf) (2009) 1.94
MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer (2009) 1.87
Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol (1999) 1.86
Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab (2013) 1.81
A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res (2000) 1.64
Lean phenotype and resistance to diet-induced obesity in vitamin D receptor knockout mice correlates with induction of uncoupling protein-1 in white adipose tissue. Endocrinology (2008) 1.58
[Origin of cancer cells]. Oncologia (1956) 1.52
Concepts of citrate production and secretion by prostate. 1. Metabolic relationships. Prostate (1991) 1.52
Regional morphology and pathology of the prostate. Am J Clin Pathol (1968) 1.46
Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion. Nucleic Acids Res (2013) 1.44
MicroRNAs MiR-17, MiR-20a, and MiR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLoS One (2011) 1.40
Cancer metabolism: key players in metabolic reprogramming. Cancer Sci (2013) 1.38
Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res (2011) 1.37
MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle (2009) 1.33
MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci U S A (2013) 1.33
Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J (2010) 1.32
Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res (2010) 1.30
1alpha,25-Dihydroxyvitamin D3 modulates human adipocyte metabolism via nongenomic action. FASEB J (2001) 1.29
MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells. Hum Mol Genet (2012) 1.26
Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem (2003) 1.25
Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiol (2009) 1.24
The vitamin D receptor in cancer. Proc Nutr Soc (2008) 1.22
Knockout of Slc25a19 causes mitochondrial thiamine pyrophosphate depletion, embryonic lethality, CNS malformations, and anemia. Proc Natl Acad Sci U S A (2006) 1.21
Dietary patterns and prostate cancer risk in the National Health and Nutrition Examination Survey Epidemiological Follow-up Study cohort. Cancer Epidemiol Biomarkers Prev (2004) 1.20
Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer (2011) 1.20
β-Catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/β-catenin-signaling pathway. Oncogene (2011) 1.20
Targeted expression of human vitamin D receptor in adipocytes decreases energy expenditure and induces obesity in mice. J Biol Chem (2011) 1.19
Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clin Cancer Res (2012) 1.17
Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate (2004) 1.17
Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem J (2011) 1.16
Sunlight, vitamin D and the prevention of cancer: a systematic review of epidemiological studies. Eur J Cancer Prev (2009) 1.15
1alpha,25-dihydroxyvitamin D3 inhibits uncoupling protein 2 expression in human adipocytes. FASEB J (2002) 1.11
Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma. Int J Cancer (2012) 1.10
A comprehensive nuclear receptor network for breast cancer cells. Cell Rep (2013) 1.09
Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab (2012) 1.08
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate (2005) 1.06
Vitamin D status and cancer: new insights. Curr Opin Clin Nutr Metab Care (2007) 1.05
Concepts of citrate production and secretion by prostate: 2. Hormonal relationships in normal and neoplastic prostate. Prostate (1991) 1.05
Androgen-responsive gene database: integrated knowledge on androgen-responsive genes. Mol Endocrinol (2009) 1.04
Association between plasma 25-OH vitamin D and testosterone levels in men. Clin Endocrinol (Oxf) (2012) 1.04
Epigenetic control of a VDR-governed feed-forward loop that regulates p21(waf1/cip1) expression and function in non-malignant prostate cells. Nucleic Acids Res (2010) 1.03
Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology (1999) 1.01
Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue. Cancer Prev Res (Phila) (2013) 1.01
Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism. Eur J Clin Invest (2012) 1.00
Transcriptional regulation of the c-myc protooncogene by 1,25-dihydroxyvitamin D3 in HL-60 promyelocytic leukemia cells. J Biol Chem (1987) 1.00
Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. Eur J Cancer (2010) 0.97
The inhibitory role of Mir-29 in growth of breast cancer cells. J Exp Clin Cancer Res (2013) 0.97
Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer (2010) 0.97
Androgenic control of glycolysis, the pentose cycle and pyruvate dehydrogenase in the rat ventral prostate. J Steroid Biochem (1981) 0.96
Expanding roles of vitamin D. J Clin Endocrinol Metab (2009) 0.95
Clinical trials involving vitamin D analogs in prostate cancer. Cancer J (2005) 0.94
miR-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence. J Cell Physiol (2014) 0.93
Calcitriol in the treatment of prostate cancer. Anticancer Res (2006) 0.92
Induction of STEAP4 correlates with 1,25-dihydroxyvitamin D3 stimulation of adipogenesis in mesenchymal progenitor cells derived from human adipose tissue. J Cell Physiol (2013) 0.91
Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control (2010) 0.91
Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol (2013) 0.91
The agouti gene product inhibits lipolysis in human adipocytes via a Ca2+-dependent mechanism. FASEB J (1998) 0.91
Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells. Biochem Biophys Res Commun (1996) 0.90
The evidence that the DNC (SLC25A19) is not the mitochondrial deoxyribonucleotide carrier. Mitochondrion (2008) 0.90
Vitamin D and prostate cancer: biologic interactions and clinical potentials. Cancer Metastasis Rev (1999) 0.88
Regulation of citrate metabolism by androgen in the LNCaP human prostate carcinoma cell line. Endocrine (1995) 0.88
1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology (2010) 0.88
Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr (2003) 0.87
miR-371-5p down-regulates pre mRNA processing factor 4 homolog B (PRPF4B) and facilitates the G1/S transition in human hepatocellular carcinoma cells. Cancer Lett (2013) 0.87
Characterization of the GufA subfamily member SLC39A11/Zip11 as a zinc transporter. J Nutr Biochem (2013) 0.86
25-hydroxyvitamin D₃ and 1,25-dihydroxyvitamin D₃ promote the differentiation of human subcutaneous preadipocytes. PLoS One (2012) 0.86
A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer (2006) 0.86
Indirect androgenic control of citrate accumulation in rat ventral prostate. Arch Androl (1982) 0.85
Retinoic acid and androgen receptors combine to achieve tissue specific control of human prostatic transglutaminase expression: a novel regulatory network with broader significance. Nucleic Acids Res (2012) 0.85
Enhanced effects of 1,25(OH)(2)D(3) plus genistein on adipogenesis and apoptosis in 3T3-L1 adipocytes. Obesity (Silver Spring) (2008) 0.85
Induction of differentiation by 1alpha-hydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors. Eur J Cancer (2000) 0.85
Vitamin D and androgen regulation of prostatic growth. J Cell Biochem (2003) 0.84
A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Res (2009) 0.84
1α,25-Dihydroxyvitamin D3 exerts tissue-specific effects on estrogen and androgen metabolism. Biochim Biophys Acta (2011) 0.83
Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. J Steroid Biochem Mol Biol (2010) 0.83
Spatial patterns of localized-stage prostate cancer incidence among white and black men in the southeastern United States, 1999-2001. Cancer Epidemiol Biomarkers Prev (2010) 0.82
Testosterone regulates pyruvate dehydrogenase activity of prostate mitochondria. Horm Metab Res (1993) 0.81
The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth. Biochem Biophys Res Commun (2004) 0.81
A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int (2008) 0.81
Testosterone regulates mitochondrial aspartate aminotransferase gene expression and mRNA stability in prostate. J Steroid Biochem Mol Biol (1993) 0.81
Triiodothyronine modulates growth, secretory function and androgen receptor concentration in the prostatic carcinoma cell line LNCaP. Mol Cell Endocrinol (1995) 0.80